Group 1 - The insurance industry's scheduled interest rate research value has slightly decreased by 1 basis point to 1.89%, indicating a stable sales environment during the "opening red" period [5][6][7] - The "opening red" sales are robust, driven by the migration of deposits and the improved competitiveness of dividend insurance products, leading to significant growth in new premium income for leading insurance companies [7][8] - The long-term interest rates have stabilized, enhancing the investment yield flexibility for insurance companies, with a focus on increasing allocations in high-dividend financial sectors and technology fields [8][9] Group 2 - The U.S. dollar has depreciated significantly, with President Trump expressing a preference for a weaker dollar to boost the economy, raising concerns about potential currency interventions similar to the Plaza Accord [12][14][15] - The market is skeptical about the feasibility of a "Plaza Accord 2.0," as the current geopolitical landscape and lack of support from Western allies may hinder coordinated currency interventions [14][15][16] - Trump's administration appears to be prioritizing economic sustainability over maintaining dollar hegemony, which could lead to capital outflows and asset value depreciation [16] Group 3 - In December 2025, the profits of industrial enterprises showed a year-on-year increase of 0.6%, driven by contributions from investment income and non-recurring gains, despite not reflecting significant operational improvements [18][19] - The profit margin for industrial enterprises improved significantly, with a notable increase in revenue profit margins, indicating a recovery in profitability [19][20] - The performance of high-tech manufacturing sectors was particularly strong, with profit growth rates for specific segments like semiconductors and smart devices reaching as high as 172.6% [21][22]

Investment Rating - The industry investment rating is "Overweight," indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [6]. Core Insights - The report highlights a slight decrease in the preset interest rate research value for ordinary life insurance products, now at 1.89%, with limited downward adjustment potential for the year [4]. - The "New Year Sales" for insurance products are robust, driven by deposit migration and improved competitiveness of dividend insurance, leading to significant growth in new premium income for leading insurance companies [4]. - Long-term interest rates are stabilizing, enhancing the investment yield elasticity for insurance companies, with increased allocations towards equity investments in high-dividend financial stocks [4]. Summary by Sections Investment Highlights - The preset interest rate for ordinary life insurance products has decreased by 1 basis point to 1.89%, with a gradual decline observed since Q4 2024 [4][5]. - The "New Year Sales" period shows strong performance, with leading insurance firms experiencing substantial growth in new premium income, particularly in dividend insurance [4]. - The stability of long-term interest rates around 1.8% is expected to support a steady increase in net investment returns for insurance companies [4]. Market Trends - The report notes a significant increase in market trading sentiment, which is expected to create investment opportunities within the non-bank financial sector [3]. - The insurance sector is witnessing a shift towards dividend insurance products, which are becoming the main sales drivers, reflecting a preference for products that offer both guaranteed and variable returns [4]. Investment Recommendations - The report suggests continued attention to the transformation of life insurance liabilities and the potential for demand release as consumer awareness of insurance products increases [4]. - It emphasizes the importance of large listed insurance companies with strong competitive advantages, particularly in the context of the current low valuation environment [4].

Group 1: Economic Context - The joint intervention by the US and Japan in the yen is primarily to prevent risks associated with rising US Treasury yields, rather than to weaken the dollar[2] - Trump's administration is actively seeking a "weak dollar" to boost the US economy, which may not receive support from Western allies[2] - The current geopolitical tensions, particularly regarding Greenland and Denmark, have created a significant rift between the US and Europe, reducing the likelihood of coordinated currency interventions[2] Group 2: Market Reactions - On January 27, 2026, following Trump's comments on the dollar, it depreciated by over 1.2%, reaching a low of 95.55, the lowest since February 2022[3] - Gold prices surged, exceeding $5200 per ounce on January 28, 2026, in response to the dollar's decline[3] - Trump's remarks about manipulating the dollar like a yo-yo challenge the independence of the Federal Reserve, raising concerns about market stability[3] Group 3: Future Implications - The potential for a "Plaza Accord 2.0" is considered low due to the complexities of unilateral currency appreciation and the current geopolitical landscape[4] - A reduction in the US current account deficit could lead to capital outflows and asset devaluation, threatening the stability of the dollar's dominance[4] - Risks include unexpected inflation in the US and faster-than-expected recovery in the domestic economy, which could impact market dynamics[4]

Group 1: Non-Bank Financial Industry - The public fund performance benchmark has officially been implemented, with the preset interest rate research value decreasing by 1 basis point week-on-week [6][7] - The non-bank index fell by 1.5%, underperforming the CSI 300 by 0.9 percentage points, with both brokerage and insurance indices showing a synchronized decline of -0.6% and -4% respectively [6][7] - The average daily trading volume of stock funds decreased by 15.8% week-on-week to 34,429 billion yuan, while the margin financing balance slightly decreased by 0.3% to 2.72 trillion yuan [6] Group 2: TuoJing Technology (688072) - TuoJing Technology is a leading domestic semiconductor thin film deposition equipment company, with a significant revenue increase from 440 million yuan in 2020 to 4.1 billion yuan in 2024, reflecting a compound annual growth rate of 75% [11][12] - The company has established a dual-platform driven structure focusing on thin film deposition and advanced bonding equipment, with a strong market demand evidenced by an order backlog of approximately 9.4 billion yuan, a year-on-year increase of about 46% [11][12] - The global thin film deposition equipment market is projected to reach approximately 24.4 billion USD by 2025, with the domestic market estimated at around 10.2 billion USD, indicating substantial room for domestic substitution [12][13] Group 3: Food and Beverage Industry - The average price of raw milk has remained low, with a current price of 3.03 yuan per kilogram, reflecting a slight increase of 0.01 yuan week-on-week, while the industry is approaching a supply-demand turning point [16][17] - The restaurant sector is showing signs of recovery, with December 2025 retail sales of social consumer goods reaching 45,136 billion yuan, a year-on-year increase of 0.9%, and restaurant income growing by 2.2% year-on-year [16][17] - The food and beverage sector saw a decline of 1.41%, underperforming the CSI 300 index by 0.79 percentage points, with snack foods performing well, increasing by 6.12% [18][19]

Investment Rating - The report assigns an "Overweight" rating to the non-bank financial sector, indicating that the sector is expected to outperform the broader market index (CSI 300) by at least 10% over the next six months [4]. Core Insights - The report highlights the recent decline in the non-bank financial index, which fell by 1.5%, underperforming the CSI 300 by 0.9 percentage points. The brokerage and insurance indices also experienced declines of 0.6% and 4%, respectively, with the insurance index showing a significant drop [4]. - The implementation of the new public fund performance benchmark guidelines is expected to stabilize product styles and enhance internal management mechanisms within the industry. This is anticipated to catalyze performance disclosures and improve market sentiment [4]. - The insurance sector is experiencing a slight decrease in the preset interest rate, now at 1.89%, but this is not expected to reach the adjustment threshold. The report suggests that the long-term interest rate will remain stable, enhancing product design sustainability [4]. Summary by Sections Market Review - The report notes that the average daily trading volume for stock funds was 34,429 billion yuan, a decrease of 15.8% from the previous week. The margin financing balance slightly decreased by 0.3% to 2.72 trillion yuan, while the stock pledge market value increased by 3% to 3.17 trillion yuan [4][16]. Brokerage Insights - The new public fund performance benchmark guidelines, effective from March 1, are expected to stabilize fund management practices and enhance long-term performance assessments. The report emphasizes the importance of monitoring deviations from benchmarks to protect investor interests [4]. - Recent earnings forecasts from listed brokerages indicate a significant improvement in performance driven by market elasticity, suggesting potential positive catalysts for the sector [4]. Insurance Insights - The report indicates that the insurance sector is seeing a trend of increasing confidence as major insurers are launching products with higher preset interest rates to attract funds from the banking sector. This is expected to boost sales during the "opening season" [4]. - The report also highlights that the active trading in the A-share market, driven by favorable policies and economic recovery expectations, is enhancing market sentiment towards the insurance sector [4]. Investment Recommendations - For brokerages, the report suggests focusing on opportunities related to mergers and acquisitions, wealth management transformation, and enhancing return on equity (ROE). It recommends investing in large brokerages with strong capital and stable operations [4]. - In the insurance sector, the report advises monitoring large comprehensive insurers with competitive advantages, especially in the context of high-quality development under stringent regulatory frameworks [4].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [6][7]. Core Insights - The company is a leading domestic semiconductor thin film deposition equipment manufacturer, demonstrating rapid revenue growth that confirms its industry-leading position. The company has established a dual-platform driven structure centered on thin film deposition equipment and advanced bonding and supporting measurement equipment. From 2020 to 2024, revenue is projected to grow from 440 million to 4.1 billion yuan, with a compound annual growth rate (CAGR) of 75% [6][7]. - The company is well-positioned to capitalize on the trends of advanced processes and three-dimensional integration, with its thin film deposition business continuing to grow significantly. The global thin film deposition equipment market is expected to reach approximately $24.4 billion by 2025, with the domestic market estimated at around $10.2 billion, indicating substantial room for domestic substitution [6][7]. - The company is strategically expanding into advanced bonding and supporting measurement equipment, which is crucial for achieving high-density, high-performance, and low-power chips, particularly driven by AI applications. The advanced packaging market is projected to grow from $4.3 billion in 2023 to $28 billion by 2029, with a CAGR of about 37% [6][7]. Summary by Sections 1. Company Overview - The company has focused on high-end semiconductor equipment since its establishment in 2010, developing a comprehensive product matrix in thin film deposition and three-dimensional integration equipment [13][15]. - The company has a balanced shareholding structure without a controlling shareholder, with the largest shareholder holding 19.57% [18][21]. 2. Market Opportunities - Thin film deposition is a core process in integrated circuit manufacturing, essential for constructing multi-layer circuit structures and enhancing device performance. The company’s products cover a wide range of applications in logic and memory chip manufacturing [45][46]. - The company’s thin film deposition equipment has shown excellent stability in client production lines, with an average uptime exceeding 90%, matching international standards [6][7]. 3. Financial Performance - The company’s revenue has maintained a high growth trajectory, with a CAGR of 75.19% from 2020 to 2024. In the first three quarters of 2025, revenue reached 4.22 billion yuan, a year-on-year increase of 85.27% [23][27]. - The company’s net profit has been on a continuous rise since turning profitable in 2021, with a net profit of 557 million yuan in the first three quarters of 2025, reflecting a significant year-on-year growth of 105.14% [27][30]. 4. Future Growth Potential - The company has a robust order backlog, with approximately 9.4 billion yuan in orders as of 2024, representing a year-on-year increase of about 46%. This strong demand underlines the company’s market position and customer recognition [27][41]. - The company is continuously optimizing its cost structure, enhancing operational and R&D efficiency, which is expected to improve profit margins as new products enter mass production [27][30].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [6][7]. Core Insights - The company is a leading domestic semiconductor thin film deposition equipment manufacturer, demonstrating rapid revenue growth that confirms its industry-leading position. The revenue is projected to grow from 440 million yuan in 2020 to 4.1 billion yuan in 2024, with a compound annual growth rate (CAGR) of 75% [6][7]. - The company has established a dual-platform strategy focusing on thin film deposition equipment and advanced bonding and supporting measurement equipment, which enhances its technological capabilities and market position [6][7]. - The global thin film deposition equipment market is expected to reach approximately $24.4 billion by 2025, with the domestic market estimated at around $10.2 billion, indicating significant room for domestic substitution as the current localization rate is below 20% [6][7]. Summary by Sections 1. Company Overview - The company has been focusing on high-end semiconductor equipment since its establishment in 2010, developing a comprehensive product matrix that includes PECVD, ALD, SACVD, HDPCVD, and Flowable CVD technologies [13][15]. - The company has successfully launched its first wafer-to-wafer (W2W) hybrid bonding equipment, expanding its product offerings in the three-dimensional integration equipment sector [13][15]. 2. Market Opportunities - The thin film deposition process is critical in semiconductor manufacturing, responsible for constructing multi-layer circuit structures and enhancing device performance [45]. - The advanced packaging market is projected to grow from $4.3 billion in 2023 to $28 billion by 2029, with a CAGR of approximately 37%, highlighting the increasing demand for hybrid bonding equipment [6][7]. 3. Financial Performance - The company’s revenue is expected to reach 6.38 billion yuan in 2025, with a year-on-year growth rate of 55.52%, and net profit is projected to be 1.04 billion yuan, reflecting a growth rate of 51.32% [8][7]. - The company has a robust order backlog of approximately 9.4 billion yuan as of the end of 2024, indicating strong market demand and customer recognition [6][7]. 4. Product Development and R&D - The company has invested significantly in R&D, with a total of 1,783 patent applications filed, of which 581 have been granted, demonstrating its commitment to innovation [33][27]. - The company’s thin film deposition equipment has achieved a stable operational uptime of over 90%, matching international standards, which enhances its competitive edge [6][7]. 5. Management and Corporate Structure - The company has a balanced shareholding structure with no controlling shareholder, which promotes efficient and collaborative operations [18][21]. - The management team possesses extensive industry experience and a strong technical background, supporting the company’s ongoing innovation and business expansion [21][22].

[Table_Reportdate] 2026年01月27日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 陈伟业 cwy@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20260127 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.药品零售新政出台，赋能行业高质量发展——医药生物行业周报（2026/01/19- 2026/01/25） ➢ 2.2026年全球AI服务器出货同比有望增超28%，AI相关芯片涨价持续——电子行业周报 2026/1/19-2025/1/25 ➢ 1.商务部：将优化实施消费品以旧换新，促进家电等大宗耐用商品消费 ➢ 2.上期所调整白银、锡期货相关合约交易限额 ➢ 3.香港特别行政区行 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry is expected to outperform the broader market index (CSI 300) by at least 10% over the next six months [1]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.39% during the week of January 19-23, 2026, ranking 27th among 31 sectors, while outperforming the CSI 300 index by 0.23 percentage points. The current PE valuation for the sector stands at 30.27 times, which is at the historical median level, with a valuation premium of 126% compared to the CSI 300 [5][16][23]. - The top-performing sub-sectors during this period were pharmaceutical commerce (4.26%), traditional Chinese medicine II (0.89%), and medical devices (0.30%) [5][14]. - A total of 330 stocks (69.62%) in the sector rose, while 137 stocks (28.90%) fell. The top five gainers included *ST Changyao (70.37%), Hualan Biological Engineering (32.21%), and Kangzhong Medical (25.47%) [5][31]. Market Performance - The pharmaceutical and biotechnology sector's performance for the year-to-date shows an increase of 6.66%, ranking 16th among 31 sectors and outperforming the CSI 300 index by 5.10 percentage points. The sub-sectors that achieved growth included medical services (13.53%), medical devices (9.50%), and pharmaceutical commerce (7.77%) [16][22]. - The PE valuations for various sub-sectors are as follows: medical devices (36.13), chemical pharmaceuticals (34.34), biological products (33.61), medical services (32.89), traditional Chinese medicine II (22.22), and pharmaceutical commerce (17.16) [23][30]. Industry News - On January 22, 2026, nine government departments, including the Ministry of Commerce and the National Health Commission, jointly issued guidelines aimed at promoting high-quality development in the pharmaceutical retail industry. The policy focuses on six key areas, emphasizing a combination of government guidance and market leadership to enhance professional and intensive development within the industry [6][33]. - The guidelines encourage the integration of pharmaceutical services, improvement of pharmacy service capabilities, and the promotion of prescription circulation and medical insurance outpatient coordination services. They also support the establishment of a commercial insurance payment system and the expansion of health management services [6][33][34]. Investment Recommendations - The report suggests a cautious approach to the pharmaceutical and biotechnology sector, highlighting the recent weak performance of previously popular stocks. It emphasizes the importance of the new guidelines in transforming the industry from a "single drug sales" model to a "health service" model [6][34]. - The report recommends focusing on leading chain pharmacies with strong financial capabilities and merger integration abilities, as well as innovative drug chains, medical devices, healthcare services, and second-class vaccines for potential investment opportunities [6][34][7].

[Table_Reportdate] 2026年01月26日 1 标配 行 业 周 报 [Table_Authors] 证券分析师 方霁 S0630523060001 fangji@longone.com.cn 联系人 董经纬 djwei@longone.com.cn 联系人 方逸洋 fyy@longone.com.cn [table_stockTrend] [table_product] 相关研究 1.台积电CapEX超预期，2025 年智能手机出货实现韧性增长 ——电子行业周报2026/1/12- 2025/1/18 1. 台积电CapEX超预期，2025年智 能手机出货实现韧性增长——电子 行业周报（20260112-20260118） 2. 英伟达Rubin平台正式发布，台 积电2025全年营收创新高——电子 行业周报（20260105-20260111） 3. 英伟达获Groq推理技术授权，中 芯国际对部分产能实施涨价——电 子行业周报（20251222- 20251228） [Table_NewTitle] 2026年全球AI服务器出货同比有望增超 28%，AI相关芯片涨价持续 ——电子行业周报2 ...